ARCHIVES

Phase III Trial of Alimta, Avastin Combination Fails Endpoint to Improve Overall Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 9 | September 28, 2012

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities: ONS Biotherapy Phase II, Outcomes-Research Grant

August 3, 2001

In Brief: Harold Moses Directs Vanderbilt Cancer Center; Carl Fretts, NIH contracts Director, To Retire

June 11, 1993

NCI CTEP-Approved Trials For the Month of February

February 28, 2014

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

September 27, 2002

ImClone Protocol Generates More Questions Than Answers

March 8, 2002

Litton Sells Clinical Labs, Planning to Join Recompetition For FCRF Contracts

July 12, 1985